Onxeo’s Combined General Meeting of Shareholders

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--

Regulatory News:

Onxeo S.A. (Paris: ONXEO) (NASDAQ OMX: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the General Meeting, held at the company’s headquarters in Paris, France on May 20, 2015, adopted all of the resolutions recommended by the Board of Directors.

Please be advised that the voting results of the Combined General Meeting are available on our website www.onxeo.com, in the section “Investors/General meetings”.

About OnxeoOnxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to “make the difference”. The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinomaValidive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line resultsBeleodaq® (belinostat): registered in the US in peripheral T-cell lymphomaFor more information, visit the website www.onxeo.com

DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (http://www.amf-france.org) or on the company’s website (www.onxeo.com).

To receive our press releases and newsletters, please register on: http://www.onxeo.com/en/newsletter/Follow us on twitter @Onxeo_

View source version on businesswire.com: http://www.businesswire.com/news/home/20150520006087/en/

Onxeo S.A.
Judith Greciet, CEO
[email protected]
Nicolas Fellmann, CFO
[email protected]
+33 1 45 58 76 00
or
Caroline Carmagnol / Sophie Colin – Alize RP
[email protected]
+33 6 64 18 99 59 / +33 1 44 54 36 62

Source: Onxeo S.A.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Uzbekistan Hosts 38th International Olympiad in Informatics, Cementing Role as Central Asia’s Leading IT Hub
• Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™
• Balfour Beatty Communities and U.S. Army Fort Jackson Celebrate Completion of 19 New Homes at Fort Jackson Family Homes